Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
information fournie par Boursorama CP 06/10/2020 à 07:30
Ajoutez Boursorama à vos sources préférées

Strasbourg (France), Tokyo (Japan) and Waltham, MA (USA)- Oct. 6, 2020, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies and BostonGene Corporation (BostonGene), a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a strategic collaboration for two ongoing Phase 1 clinical trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers based on Transgene's proprietary myvac® platform and NEC's AI-driven Neoantigen Prediction System in Europe and the United States.

Transgene's myvac® platform brings together a series of highly innovative technologies, such as viral genome engineering, to achieve high-speed modular manufacturing of bespoke immunotherapies.

.../...

Valeurs associées

TRANSGENE
0,7250 EUR Euronext Paris -0,14%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
BIOPHYTIS
0,111 +16,84%
HAFFNER ENERGY
0,7 -2,91%
CAC 40
8 530,8 -0,57%
ATON
0,0164 -3,53%
Pétrole Brent
90,94 -0,18%
Chargement...

Pages les plus populaires

L'offre BoursoBank